Presentations and Quarterly Reports - Research Report on NPS, Zalicus, Charles River, Insulet, and Sagent

NEW YORK, November 14, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Zalicus Inc. (NASDAQ: ZLCS), Charles River Laboratories International, Inc. (NYSE: CRL), Insulet Corporation (NASDAQ: PODD), and Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

NPS Pharmaceuticals, Inc. Research Report

On November 11, 2013, NPS Pharmaceuticals, Inc. (NPS) announced that it will present at the upcoming Jefferies 2013 Global Healthcare Conference, to be held in London on Thursday, November 21, 2013 at 8:40 a.m. WET. NPS reported that to access the live webcast and replay (available three hours after the presentation), interested parties may visit its Investors' calendar of events website. The Full Research Report on NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/441a_NPSP]

--

Zalicus Inc. Research Report

On November 4, 2013, Zalicus Inc. (Zalicus) released its Q3 2013 results. Zalicus registered total revenues of $3.4 million in Q3 2013, down 3.4% YoY. The Company posted net loss of $10.5 million in Q3 2013, compared to net loss of $12.2 million in Q3 2012. Zalicus reported diluted loss per share of $0.46 in Q3 2013, compared to diluted loss per share of $0.59 in Q3 2012. Mark H.N. Corrigan, MD, President and CEO of Zalicus, announced, "We remain on track to report top-line data for the two Phase 2 clinical trials of Z160, including lumbosacral radiculopathy and postherpetic neuralgia, in the fourth quarter of 2013. In addition, based on the positive results of the Z944 Phase 1b Laser-Evoked-Potentials (LEP) study, we are planning to initiate a Phase 2 clinical study in an appropriate pain indication with a modified release formulation of Z944 next year." The Full Research Report on Zalicus Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/cbb5_ZLCS]

--

Charles River Laboratories International, Inc. Research Report

On November 11, 2013, Charles River Laboratories International, Inc. (Charles River) announced that it is presenting at the Credit Suisse 2013 Healthcare Conference in Phoenix, Arizona on Wednesday, November 13, 2013 at 11:00 a.m. MST (1:00 p.m. EST). Charles River reported that the live webcast and replay (available for two weeks beginning three hours after the presentation) can be accessed through its Investor Relations website. The Full Research Report on Charles River Laboratories International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/a37e_CRL]

--

Insulet Corporation Research Report

On November 7, 2013, Insulet Corporation (Insulet) released its Q3 2013 results. Insulet registered revenues of $61.1 million in Q3 2013, up 11.6% YoY. The Company posted net loss of $21.3 million in Q3 2013, compared to net loss of $12.4 million in Q3 2012. Insulet reported diluted loss per share of $0.39 in Q3 2013, compared to diluted loss per share of $0.26 in Q3 2012. Disclosing its guidance, the Company informed that it expects Q4 2013 revenues to be in the range of $65 million to $71 million and full-year 2013 revenues to be in the range of $244 million to $250 million. The Full Research Report on Insulet Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/75e4_PODD]

--

Sagent Pharmaceuticals, Inc. Research Report

On November 5, 2013, Sagent Pharmaceuticals, Inc. (Sagent) released its Q3 2013 results. Sagent registered net revenues of $60.8 million in Q3 2013, up 23.1% YoY. The Company posted net income of $2.8 million in Q3 2013, compared to net loss of $3.8 million in Q3 2012. Sagent reported diluted EPS of $0.10 in Q3 2013, compared to diluted loss per share of $0.13 in Q3 2012. Commenting on the results, Jeffrey M. Yordon, CEO and Chairman of the Board of Sagent, said, "Our third quarter results reflect another solid quarter of financial performance driven by balanced demand across our diverse product portfolio. The continued strong earnings performance, and related cash flow, has enabled intensified investment in our product portfolio through both external development partners and through SCP, our wholly owned venture in China." Yordon continued, "In addition to the positive earnings and cash flow contributions, the success of our recently completed secondary offering bolsters our resources for long-term investment in SCP, development of our product portfolio and pursuit of strategic growth drivers." The Full Research Report on Sagent Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/a901_SGNT]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner